Hongjie Shen

Hongjie Shen

Auto-generated profile, based on publicly available information

Hongjie Shen

Longevity and Aging Institute, the Shanghai Key Laboratory of Medical Epigenetics, Institutes of Biomedical Sciences, Department of Pancreatic Surgery, Zhongshan Hospital, Fudan University, Shanghai, China

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 January 2021 in Nature
Verified
Journal Article
Closed access
PDF file
WXWenqi Xu
Wenqi Xu
JLJiahui Li
Jiahui Li
CHChenxi He
Chenxi He
JWJing Wen
Jing Wen
HMHonghui Ma
Honghui Ma
HSHongjie Shen
Hongjie Shen

25 February 2022 in Molecular Cell
Verified
Journal Article
Closed access
WXWenqi Xu
Wenqi Xu
CHChenxi He
Chenxi He
EKEmily G. Kaye
Emily G. Kaye
JLJiahui Li
Jiahui Li
MMMandi Mu
Mandi Mu
HSHongjie Shen
Hongjie Shen

22 October 2019 in Protein & Cell
Verified
Journal Article
Open access
PDF file
JWJiahua Wang
Jiahua Wang
LWLiyong Wang
Liyong Wang
JDJianbo Diao
Jianbo Diao
YSYujiang Geno Shi
Yujiang Geno Shi
YSYang Shi
Yang Shi
HSHongjie Shen
Hongjie Shen

22 November 2019 in Protein & Cell
Verified
Journal Article
Open access
PDF file
WXWenqi Xu
Wenqi Xu
JLJiahui Li
Jiahui Li
BRBowen Rong
Bowen Rong
BZBin Zhao
Bin Zhao
MWMei Wang
Mei Wang
FLFei Lan
Fei Lan

13 June 2023 in Cell Reports
Verified
Journal Article
Open access
MMMandi Mu
Mandi Mu
XLXinze Li
Xinze Li
LDLi Dong
Li Dong
JWJin Wang
Jin Wang
QCQingqing Cai
Qingqing Cai
HSHongjie Shen
Hongjie Shen
METTL14 (methyltransferase-like 14) is an RNA-binding protein that partners with METTL3 to mediate N6-methyladenosine (m6A) methylation. Recent studies identified a function for METTL3 in heterochromatin in mouse embryonic stem cells (mESCs), but the molecular function of METTL14 on chromatin in mESCs remains unclear. Here, we show that METTL14 specifically binds and regulates bivalent domains, which are marked by trimethylation of histone H3 lysine 27 (H3K27me3) and lysine 4 (H3K4me3). Knockout of Mettl14 results in decreased H3K27me3 but increased H3K4me3 levels, leading to increased transcription. We find that bivalent domain regulation by METTL14 is independent of METTL3 or m6A modification. METTL14 enhances H3K27me3 and reduces H3K4me3 by interacting with and probably recruiting the H3K27 methyltransferase polycomb repressive complex 2 (PRC2) and H3K4 demethylase KDM5B to chromatin. Our findings identify an METTL3-independent role of METTL14 in maintaining the integrity of bivalent domains in mESCs, thus indicating a mechanism of bivalent domain regulation in mammals.

29 July 2015 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
YXYang Xu
Yang Xu
YSYanjun Sun
Yanjun Sun
HSHongjie Shen
Hongjie Shen
LIN DINGLIN DING
LIN DING
ZYZhen Yang
Zhen Yang
DWDepei Wu
Depei Wu
DNMT3A mutations are frequent in cytogenetically normal acute myeloid leukemia (cn‐AML) patients and associated with poor survival. The role of allogeneic hematopoietic stem cell transplantation (allo‐HSCT) in DNMT3Amut cn‐AML patients remains unclear. In this study, we retrospectively analyzed the prognostic impact of DNMT3A mutations and explored the role of allo‐HSCT in 308 cn‐AML patients who received consolidation of intensive chemotherapy or allo‐HSCT in our center from March 2005 to May 2014. In the whole cohort, 63 patients (20.5%) were identified with DNMT3A exon 23 mutations and R882H was the most frequent variant. DNMT3Amut patients had shorter overall survival (3‐year OS: 31.9% vs. 52.0%, P = 0.009) and disease‐free survival (3‐year DFS: 21.8% vs. 40.1%, P = 0.004) compared with DNMT3Awt patients. Based on FLT3/NPM1/CEBPA mutations, 308 cn‐AML patients were divided into favorable/intermediate group (n = 262) and unfavorable group (n = 46). There were no significant differences in 3‐year OS and 3‐year DFS between DNMT3Amut and DNMT3Awt patients in both favorable/intermediate and unfavorable groups. Additionally, in multivariate analysis, DNMT3A mutation remained an independent adverse prognostic factor for the survival. In the DNMT3Amut cohort, 23 complete remission (CR) patients received allo‐HSCT consolidation and 32 CR patients received chemotherapy consolidation, dramatic differences were observed in 3‐year OS (51.7% vs. 28.9%, P = 0.048) and 3‐year DFS (41.6% vs. 14.9%, P = 0.024) between allo‐HSCT group and chemotherapy group. Collectively, DNMT3A mutation is a poor prognostic factor for cn‐AML patients and allo‐HSCT could improve survival of cn‐AML patients with DNMT3A mutations. Am. J. Hematol. 90:992–997, 2015.